Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)

NCT01098110 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT01098110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01098110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
May 25, 2010
Completion date
April 14, 2014
Enrollment
532 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia